Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells

Mol Pharm. 2010 Jun 7;7(3):914-20. doi: 10.1021/mp900316a.

Abstract

Current chemotherapy regimens against pancreatic cancer are met with little success as poor tumor vascularization significantly limits the delivery of oncological drugs. High-dose targeted drug delivery, through which a drug delivery vehicle releases a large payload upon tumor localization, is thus a promising alternative strategy against this lethal disease. Herein, we synthesize anti-carcinoembryonic antigen (CEA) half-antibody conjugated lipid-polymer hybrid nanoparticles and characterize their ligand conjugation yields, physicochemical properties, and targeting ability against pancreatic cancer cells. Under the same drug loading, the half-antibody targeted nanoparticles show enhanced cancer killing effect compared to the corresponding nontargeted nanoparticles.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoembryonic Antigen / metabolism*
  • Cell Line
  • Chromatography, High Pressure Liquid
  • Drug Delivery Systems / methods*
  • Humans
  • Lipids / chemistry*
  • Nanoparticles / chemistry*
  • Paclitaxel / administration & dosage
  • Paclitaxel / chemistry
  • Paclitaxel / therapeutic use
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / metabolism*
  • Polymers / chemistry*

Substances

  • Carcinoembryonic Antigen
  • Lipids
  • Polymers
  • Paclitaxel